One MG patient’s story sparked Canopy’s mission: replacing broad immunosuppression with targeted immune reprogramming designed to deliver durable, disease-modifying remission.
“We’re not looking for incremental improvement. Aspirational, but we’re aiming for cure.”
Meeting Natalie during medical school inspired a decade-long mission: selectively eliminating disease-causing autoantibodies and cells while preserving protective immunity.
Founded in 2020 by Dr. Kfir Oved, Canopy was founded to develop precision therapies that target the root cause of autoimmune disease without suppressing the immune system.
From day one, the goal was never better immunosuppression, but a fundamentally better, science-driven treatment approach that will provide patients the hope for a healthy future.
%201.svg)
To redefine autoimmune care by replacing lifelong management with durable, treatment-free remission and a true cure.
To develop the first-in-class, non-immunosuppressive, potentially curative therapies for antibody-mediated autoimmune diseases.
We move fast, stay focused, and invest effort only where it meaningfully advances patients and science.
Autoimmune biology is complex. We let the data lead, respect uncertainty, and listen closely to patients, collaborators, and science itself.
We take bold, disciplined risks to achieve outcomes that incremental thinking cannot deliver while keeping the patients at the center of our goals.
Canopy’s first-in-class Antigen-Drug Conjugates (AgDCs) are designed to redefine treatment of antibody-mediated autoimmune diseases by replacing chronic immunosuppression with targeted immune reprogramming aimed at durable, disease-modifying, symptom-free remission.